Bristol Myers Squibb (BMY) Expands CAMZYOS Approval, Is The Stock Still A Bargain?

Bristol-Myers Squibb (BMY) just received expanded FDA approval for CAMZYOS in symptomatic obstructive hypertrophic cardiomyopathy, now including eligible pediatric patients. This development sharpens the focus on how this cardiac franchise feeds into the broader equity story.

CAMZYOS’ broader label arrives after a mixed stretch for Bristol-Myers Squibb’s stock, with a 1-day share price return of 1.33% following the news, a 7-day share price decline of 5.20%, and a 30-day share price drop of 10.82%. This contrasts with an 11.47% year-to-date share price gain and a 39.37% total shareholder return over the past year, which together indicate that longer term momentum has been building even as short term sentiment has cooled and investors reassess risk and growth potential across the pipeline.

Spot 27 high quality undervalued stocks that, like Bristol-Myers Squibb after the CAMZYOS approval, pair established franchises with fresh clinical catalysts that could reshape market expectations.

Bristol-Myers Squibb now trades at US$59.59, while analyst targets cluster nearer US$66 and some intrinsic value models point much higher. Where does a reasonable view of fair value actually land after this move?

Most Popular Narrative: 10.7% Undervalued

Bristol-Myers Squibb’s most followed valuation narrative pegs fair value at about $66.71, which sits above the latest close at $59.59 and frames today’s discount as modest rather than extreme.

Ongoing shift in Bristol-Myers Squibb’s revenue mix toward its growth portfolio, which reached $7.6b in Q2 2026 and nearly 60% of total sales, supports the view that new products can increasingly offset legacy erosion and underpin future revenue and earnings.

See why 228 investors see Bristol-Myers Squibb as 11% undervalued.

Result: Fair Value of $66.71 (UNDERVALUED)

Still, Bristol-Myers Squibb faces two clear pressure points: faster than expected erosion after major patent expiries and any further safety or delay issues across key late stage programs.

Find out about the key risks to this Bristol-Myers Squibb narrative.

Next Steps

Mixed signals on Bristol-Myers Squibb’s outlook can be confusing, so consider acting promptly, review the full risk and reward stack, and shape your own stance with 4 key rewards and 3 important warning signs

Looking for more Bristol-Myers Squibb style investment ideas?

If you are serious about sharpening your portfolio after the Bristol-Myers Squibb news, use focused screeners to surface candidates that match your risk and income goals.

• Target sturdier balance sheets by reviewing companies in the list of solid balance sheet and fundamentals (25 results) that can potentially handle setbacks without constant refinancing pressure.
• Hunt for potential mispricings through the 27 high quality undervalued stocks and avoid leaving possible value opportunities sitting on the sidelines.
• Build a steadier income base by scanning the 8 dividend fortresses and stress testing which payouts might hold up when conditions turn tougher.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com